Protalix BioTherapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $52.7M | $53.4M | $65.5M | $47.6M | $38.4M | $62.9M | $54.7M |
| Cost of Revenue | — | $27.0M | $24.3M | $23.0M | $19.6M | $16.3M | $10.9M | $10.9M |
| Gross Profit | — | $25.8M | $29.1M | $42.5M | $28.0M | $22.0M | $52.0M | $43.8M |
| Gross Margin | — | 48.8% | 54.5% | 64.9% | 58.9% | 57.4% | 82.7% | 80.1% |
| Operating Expenses | ||||||||
| Research & Development | — | $19.6M | $13.0M | $17.1M | $29.3M | $29.7M | $38.2M | $44.6M |
| SG&A Expense | — | $11.7M | $12.2M | $15.0M | $11.7M | $12.7M | $11.1M | $9.9M |
| Operating Income | — | $-5.5M | $3.9M | $10.5M | $-13.0M | $-20.5M | $2.7M | $-10.7M |
| Operating Margin | — | -10.4% | 7.3% | 16.0% | -27.3% | -53.4% | 4.3% | -19.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-5.6M | $4.2M | $8.6M | $-14.4M | $-27.6M | $-6.5M | — |
| Income Tax Expense | — | $996.0K | $1.2M | $254.0K | $530.0K | — | — | — |
| Net Income | — | $-6.6M | $2.9M | $8.3M | $-14.9M | $-27.6M | $-6.5M | $-18.3M |
| Net Margin | — | -12.5% | 5.5% | 12.7% | -31.3% | -71.9% | -10.4% | -33.4% |
| EPS (Basic) | — | $-0.08 | $0.04 | $0.12 | $-0.31 | $-0.62 | $-0.22 | $-1.23 |
| EPS (Diluted) | — | $-0.08 | $0.04 | $0.09 | $-0.31 | $-0.62 | $-0.22 | $-1.23 |
| Shares Outstanding (Basic) | 80.6M | 78.5M | 72.5M | 67.5M | 48.5M | 44.1M | 29.1M | 14.8M |
| Shares Outstanding (Diluted) | 80.6M | 78.5M | 81.1M | 82.4M | 48.5M | 44.1M | 29.1M | 14.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |